Ricardo Defense awarded a sole-source contract valued at over $89M to deliver 9,480 ABS/ESC retrofit kits to US Army
The Army today awarded Ricardo Defense a base contract to provide up to 9,480 critical safety improvement Antilock Brake System / Electronic Stability Control (ABS/ESC) retrofit kits over the next three years for the U.S. Army’s High Mobility Multipurpose Wheeled Vehicle (HMMWV). The first delivery order, under the three-year base contract, will include $10M to deliver 1,200 ABS/ESC retrofit kits by August 2021. A second delivery order is expected later this year to increase deliveries to approximately 2,000 ABS/ESC retrofit kits over the next 12 months.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210317005179/en/
High Mobility Multipurpose Wheeled Vehicle (HMMWV) (Photo: Business Wire)
Historical data presented by the National Highway Traffic Safety Administration (NHTSA) indicates that the application of ABS and ESC reduces the number of fatal rollovers by 74%, and fatal impacts by 45%. Today’s initial award marks the beginning of a multi-year contract for Ricardo Defense to improve the safety and operational readiness of the fielded HMMWV fleet for U.S. soldiers and HMMWV operators worldwide.
Chet Gryczan, president of Ricardo Defense said: “This is a significant milestone and strong example of Ricardo Defense’s commitment to provide solutions to meet the tough challenges facing our customers and ensure the safety of our men and women in uniform. In fielding this system, we are tremendously proud to contribute to the Army’s commitment to the safety of our soldiers and civilians alike.”
The HMMWV is projected to remain in the U.S. Army’s fleet until 2050. In 2018, the Army mandated that all new HMMWVs coming off the new vehicle production line must have the ABS/ESC system installed. Since July 2018, more than 5,000 new production or Recapitalized HMMWV vehicles have been delivered to the US Army with Ricardo’s ABS/ESC technology. In 2019, the Army provisioned Ricardo’s ABS/ESC retrofit kit into the national stock system for retrofit of vehicles not addressed during new production or Recapitalization. This dual-approach ensures that all HMMWVs in the enduring fleet are eventually fit with the ABS/ESC rollover mitigation technology.
A spokesperson for the U.S. Army, Product Director Light Tactical Vehicles said, “The ABS/ESC retrofit contract award is a culmination of a lot of great work from all parties, and is an essential step in providing this critical safety solution to our fielded HMMWV fleet. We are extremely proud of the Army’s collaboration with Ricardo Defense to provide an affordable and attainable solution that significantly reduces loss of control incidents, vehicle rollover incidents, and ultimately helps save lives.”
Red River Army Depot, in partnership with Ricardo Defense, will complete ABS/ESC retrofit installations at the Army’s Center of Industrial and Technical Excellence for tactical wheeled vehicles in Texarkana, Texas and at regional sites across the U.S. beginning in March 2021.
ENDS
About Ricardo
Ricardo plc is a world-class environmental, engineering and strategic consulting company listed on the London Stock Exchange. With over 100 years of engineering excellence, we provide exceptional levels of expertise in delivering leading edge and innovative cross sector sustainable products and solutions, helping our global customers increase efficiencies, achieve growth and create a clear and safer future. Our mission is clear –- to create a world fit for the future. For more information visit www.ricardo.com
About Ricardo Defense, Inc
Ricardo Defense Inc. is a Ricardo subsidiary delivering high-value system engineering, mission critical software, vehicle builds, and safety-critical products to the US Department of Defense as well as governments and defense industry suppliers world-wide. Ricardo Defense is a recognized leader in the integration of complex systems and acquisition planning and system support services for major defense programs around the globe.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210317005179/en/
Contact information
For Ricardo:
Kate Caulfield
Ricardo Defense
Email: kathryn.caulfield@ricardodefense.com
Telephone: (586) 899-7668
Ricardo Media Office
Gill Gibbons
Email: media@ricardo.com
Telephone: +44 (0) 7795 342804
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom